- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Valeant Holds On to Top Execs with Million-Dollar Bonus Payouts
May 18, 2016.
Forbes
reports that Valeant Pharmaceuticals is planning to pay CFO Robert L. Rosiello and executives Dr. Ari Kellen and Anne C. Whitaker $1 million retention bonuses, as well as “special equity awards” of $2.8 million, $3.8 million and $1.25 million, respectively, in the form of restricted stock units that vest over 18-months. Antoine Gara writes that these heavy retention bonuses "further indicate pay will be a big part of working for a kinder and gentler Valeant. Or," he adds, "perhaps, Valeant has become such a toxic workplace only heavy incentives can generate loyalty inside the company".
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.
